PHIL®液体栓塞剂在外周栓塞中的多中心回顾性经验:178例患者分析
这项多中心回顾性研究纳入2017至2021年五家介入放射科178例接受PHIL®外周血管内栓塞的患者,共190次手术。总体技术成功率94.7%、临床成功率92.1%,并发症率7.4%,提示PHIL®在择期和急诊外周栓塞中安全有效。
要点
- PHIL®外周栓塞总体技术成功率94.7%、临床成功率92.1%。
- 并发症率7.4%,以Grade I和III为主,Grade IV仅1例。
- PHIL®-25为最常用粘度,平均每例手术使用1.64瓶。
核心结论
- PHIL®在外周栓塞的择期和急诊场景中均表现出较高的技术成功率和临床成功率,并发症率可接受。
- 预充式注射器设计使术者可在介入开始时未计划的情况下仍能使用PHIL®。
研究设计与样本
- 纳入接受PHIL®外周血管内栓塞的患者,采用不同粘度PHIL®;排除神经放射血管内介入、同期使用其他黏性液体栓塞剂及随访不足30天者。
- 技术成功定义为PHIL®注射后靶血管最终闭塞且无需其他栓塞剂;临床成功定义为急诊栓塞后30天血流动力学恢复或择期手术后30天临床状况改善且无需额外干预。
诊断标准与关键数值
- 总体技术成功率为94.7%,总体临床成功率为92.1%。
- 并发症率为7.4%,包括Grade I 6例、Grade III 7例、Grade IV 1例。
- PHIL®-25为最常用粘度;共注射311瓶,平均每例手术1.64瓶。
临床应用与阅片要点
- PHIL®可用于外周择期栓塞(如AVMs、II型内漏、肿瘤、静脉曲张、动脉瘤、精索静脉曲张)和急诊栓塞(如出血、假性动脉瘤、咯血、阴茎异常勃起)。
- 预充式注射器便于术中临时决定使用,无需额外准备。
局限性
- 回顾性研究设计,可能存在选择偏倚和信息偏倚。
- 随访时间仅要求至少30天,缺乏长期结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This study aims to analyze safety and effectiveness of PHIL® (Microvention, CA-USA) in peripheral endovascular embolization procedures, both in elective and emergent scenarios.
MATERIALS AND METHODS: This is a multicenter retrospective study, involving 178 patients from five interventional radiology departments from January 2017 to December 2021. Patients treated by an endovascular embolization with PHIL® were included; different PHIL® viscosities were adopted. Exclusion criteria were: neuroradiological endovascular interventions, other cohesive liquid embolics adopted during the same procedure, follow-up < 30 days. Technical success was intended as definitive target vessel occlusion without the need for other embolics after PHIL® injection. Clinical success was considered as restoration of hemodynamic status in case of emergent embolization and improvement of clinical conditions in case of elective procedures, without additional interventions at 30 days.
RESULTS: Sixty-four women and 114 men, mean age 62 years (range 6-91), were evaluated. Sixty-three patients were in elective scenarios (AVMs, type-II endoleaks, tumors, varices, aneurysms, varicoceles) and 115 were in emergent settings (hemorrhage, pseudoaneurysms, hemoptysis, priapism); 190 procedures were performed in 178 patients. Overall technical and clinical success rates were 94.7% and 92.1%, respectively. The complications rate was 7.4% (6 grade-I, 7 grade-III, 1 grade-IV). PHIL®-25 was the more adopted viscosity; totally, 311 vials were injected (rate: 1.64 vial/procedure).
CONCLUSION: In this series, PHIL® proved to be a safe and effective liquid embolic in peripheral embolizations, both in elective and emergent scenarios. The pre-filled syringe preparation allowed operators to use it even when unplanned at beginning of the intervention.
引用
- Giurazza, Cionfoli, Paladini, et al. PHIL® (precipitating hydrophobic injectable liquid): retrospective multicenter experience on 178 patients in peripheral embolizations. Radiol Med. 2022. PMID: 36070065. doi:10.1007/s11547-022-01552-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。